Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.

Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, Daly MB, Godwin AK, Buys SS, Fox S, Goldgar DE, Giles GG, Hopper JL, Southey MC.

Breast Cancer Res. 2011 Jan 31;13(1):R14. doi: 10.1186/bcr2822.

2.

BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.

Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA.

JAMA. 1998 Mar 25;279(12):922-9.

PMID:
9544766
3.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

4.

Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.

de Sanjosé S, Léoné M, Bérez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P, Bosch FX, Lenoir GM, Sinilnikova OM.

Int J Cancer. 2003 Sep 10;106(4):588-93.

5.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

PMID:
11504767
6.

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.

JAMA. 2006 Mar 22;295(12):1379-88.

PMID:
16551709
7.
8.

BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.

Smith LD, Tesoriero AA, Ramus SJ, Dite G, Royce SG, Giles GG, McCredie MR, Hopper JL, Southey MC.

Eur J Cancer. 2007 Mar;43(5):823-7. Epub 2007 Feb 21.

9.

[BRCA1 germ line mutations in Chinese early-onset breast cancer patients].

Li WF, Hu Z, Liu XY, Zhang B, Cao MZ, Wang YS, Zhao L, Liu YB, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007 Oct;24(5):499-504. Chinese.

PMID:
17922413
10.

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA.

BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.

11.

BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.

Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, Klausen S, Mouridsen HT, Winther K, Fenger K, Niebuhr A, Harboe TL, Niebuhr E.

J Med Genet. 2001 Jun;38(6):361-8.

12.

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E.

J Natl Cancer Inst. 1997 Feb 5;89(3):227-38.

PMID:
9017003
13.

Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.

Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Scarpi E, Falcini F, Strada M, Morini N, Naldoni C, Amadori D, Calistri D.

Breast Cancer Res Treat. 2008 Nov;112(2):343-9. Epub 2007 Dec 20.

PMID:
18092194
14.

A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.

Kadouri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G, Shochat C, Korem S, Hamburger T, Nissan A, Abu-Halaf N, Badrriyah M, Abeliovich D, Peretz T.

BMC Cancer. 2007 Jan 18;7:14.

15.

High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.

Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T.

Clin Genet. 2010 Oct;78(4):364-72. doi: 10.1111/j.1399-0004.2010.01473.x.

PMID:
20569256
16.

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.

Breast Cancer Res. 2012 Apr 16;14(2):R66.

17.

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.

Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA.

J Clin Oncol. 2012 Jan 1;30(1):19-26. doi: 10.1200/JCO.2010.33.0068. Epub 2011 Dec 5.

PMID:
22147742
18.

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.

Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S, Athanasiou A, Gogas H, Yannoukakos D, Fountzilas G, Konstantopoulou I.

Br J Cancer. 2009 Jul 7;101(1):32-7. doi: 10.1038/sj.bjc.6605115. Epub 2009 Jun 2.

19.

Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.

Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA.

Cancer. 2000 Mar 15;88(6):1393-402.

PMID:
10717622
20.

Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.

Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC.

JAMA. 1998 Mar 25;279(12):915-21.

PMID:
9544765

Supplemental Content

Support Center